126 related articles for article (PubMed ID: 37951819)
1. Re: David D'Andrea, Francesco Soria, Rodolfo Hurle, et al. En Bloc Versus Conventional Resection of Primary Bladder Tumor (eBLOC): A Prospective, Multicenter, Open-label, Phase 3 Randomized Controlled Trial. Eur Urol Oncol. In press. https://doi.org/10.1016/j.euo.2023.07.010.
Montorsi F; Rosiello G; Gandaglia G; Salonia A; Briganti A
Eur Urol Oncol; 2024 Jun; 7(3):636. PubMed ID: 37951819
[No Abstract] [Full Text] [Related]
2. Re: David D'Andrea, Francesco Soria, Rodolfo Hurle, et al. En Bloc Versus Conventional Resection of Primary Bladder Tumor (eBLOC): A Prospective, Multicenter, Open-label, Phase 3 Randomized Controlled Trial. Eur Urol Oncol. In press. https://doi.org/10.1016/j.euo.2023.07.010.
Lombardo R; Riolo S; De Nunzio C
Eur Urol Oncol; 2023 Oct; ():. PubMed ID: 37872030
[No Abstract] [Full Text] [Related]
3. Reply to Riccardo Lombardo, Sara Riolo, and Cosimo De Nunzio's Letter to the Editor re: David D'Andrea, Francesco Soria, Rodolfo Hurle, et al. En Bloc Versus Conventional Resection of Primary Bladder Tumor (eBLOC): A Prospective, Multicenter, Open-label, Phase 3 Randomized Controlled Trial. Eur Urol Oncol. In press. https://doi.org/10.1016/j.euo.2023.07.010.
D'Andrea D; Soria F; Hurle R; Enikeev D; Kotov S; Régnier S; Xylinas E; Lusuardi L; Heidenreich A; Cai C; Frego N; Taraktin M; Ryabov M; Gontero P; Compérat E; Shariat SF;
Eur Urol Oncol; 2023 Oct; ():. PubMed ID: 37865570
[No Abstract] [Full Text] [Related]
4. Reply to Francesco Montorsi, Giuseppe Rosiello, Giorgio Gandaglia, Andrea Salonia, and Alberto Briganti's Letter to the Editor re: David D'Andrea, Francesco Soria, Rodolfo Hurle, et al. En Bloc Versus Conventional Resection of Primary Bladder Tumor (eBLOC): A Prospective, Multicenter, Open-label, Phase 3 Randomized Controlled Trial. Eur Urol Oncol 2023;6:508-15.
D'Andrea D; Soria F; Hurle R; Enikeev D; Kotov S; Régnier S; Xylinas E; Lusuardi L; Heidenreich A; Cai C; Frego N; Taraktin M; Ryabov M; Gontero P; Compérat E; Shariat SF;
Eur Urol Oncol; 2024 Jun; 7(3):639-640. PubMed ID: 37978025
[No Abstract] [Full Text] [Related]
5. Re: Francesco Soria, Marco Moschini, David D'Andrea, et al. Comparative Effectiveness in Perioperative Outcomes of Robotic versus Open Radical Cystectomy: Results from a Multicenter Contemporary Retrospective Cohort Study. Eur Urol Focus 2020;6:1233-9.
Montorsi F; Bandini M; Necchi A
Eur Urol Focus; 2022 Mar; 8(2):631-632. PubMed ID: 33824085
[No Abstract] [Full Text] [Related]
6. Reply to Francesco Montorsi, Marco Bandini, and Andrea Necchi's Letter to the Editor re: Francesco Soria, Marco Moschini, David D'Andrea, et al. Comparative Effectiveness in Perioperative Outcomes of Robotic versus Open Radical Cystectomy: Results from a Multicenter Contemporary Retrospective Cohort Study. Eur Urol Focus 2020;6:1233-9.
Soria F; D'Andrea D; Gontero P; Shariat SF
Eur Urol Focus; 2022 Mar; 8(2):633-634. PubMed ID: 33875390
[No Abstract] [Full Text] [Related]
7. Reply to Francesco Montorsi, Giorgio Gandaglia, Francesco Barletta, and Alberto Briganti's Letter to the Editor re: Piet Ost, Shankar Siva, Sugmund Brabrand, et al. PEACE V-Salvage Treatment of Oligorecurrent Nodal Prostate Cancer Metastases (STORM): Acute Toxicity of a Randomized Phase 2 Trial. Eur Urol Oncol. In press. https://doi.org/10.1016/j.euo.2023.09.007.
Zilli T; Ost P
Eur Urol Oncol; 2024 Feb; ():. PubMed ID: 38418267
[No Abstract] [Full Text] [Related]
8. Re: Francesco Soria, Matteo Rosazza, Simone Livoti, et al. Repeat Transurethral Resection (TUR) + Bacillus Calmette-Guérin (BCG) Versus Upfront Induction BCG After TUR in High-risk Non-muscle-invasive Bladder Cancer: Feasibility Phase of a Randomized Controlled Study. Eur Urol Focus. In press. https://doi.org/10.1016/j.euf.2023.10.019.
Montorsi F; Moschini M; Salonia A; Gandaglia G; Briganti A
Eur Urol Focus; 2024 Jan; ():. PubMed ID: 38272719
[No Abstract] [Full Text] [Related]
9. Re: Beat Roth, Frédéric D. Birkhäuser, Pascal Zehnder, et al. Parenteral nutrition does not improve postoperative recovery from radical cystectomy: results of a prospective randomised trial. Eur Urol. In press. http://dx.doi.org/10.1016/j.eururo.2012.05.052.
Singh BP; Dhakad U
Eur Urol; 2012 Oct; 62(4):e79; author reply e80. PubMed ID: 22817822
[No Abstract] [Full Text] [Related]
10. Re: Kristian D. Stensland, Harras Zaid, Mark Broadwin, et al. Comparative Effectiveness of Treatment Strategies for Squamous Cell Carcinoma of the Bladder. Eur Urol Oncol. In press. https://doi.org/10.1016/j.euo.2018.11.003.
Moschini M; Zamboni S; Mattei A
Eur Urol Oncol; 2019 Mar; 2(2):230. PubMed ID: 31017104
[No Abstract] [Full Text] [Related]
11. Reply to Marco Moschini, Francesco Montorsi, Andrea Salonia, Giorgio Gandaglia and Alberto Briganti's Letter to the Editor Re: Francesco Soria, Matteo Rosazza, Simone Livoti, et al. Repeat Transurethral Resection (TUR) + Bacillus Calmette-Guérin (BCG) Versus Upfront Induction BCG After TUR in High-risk Non-muscle-invasive Bladder Cancer: Feasibility Phase of a Randomized Controlled Study. Eur Urol Focus. In press. https://doi.org/10.1016/j.euf.2023.10.019.
Soria F; Gontero P
Eur Urol Focus; 2024 Jan; ():. PubMed ID: 38278711
[No Abstract] [Full Text] [Related]
12. Re: Katharina Brück, Richard P. Meijer, Joost L. Boormans, et al. Disease-free Survival of Patients with Muscle-invasive Bladder Cancer Treated with Radical Cystectomy Versus Bladder-preserving Therapy: A Nationwide Study. Int J Radiat Oncol Biol Phys. In press. https://doi.org/10.1016/j.ijrobp.2023.07.027.
Basile G; Pradere B; Lenfant L; Rouprêt M; Seisen T
Eur Urol Oncol; 2024 Jun; 7(3):637-638. PubMed ID: 37978023
[No Abstract] [Full Text] [Related]
13. Re: Karim A. Touijer, Daniel D. Sjoberg, Nicole Benfante, et al. Limited Versus Extended Pelvic Lymph Node Dissection for Prostate Cancer: A Randomized Clinical Trial. Eur Urol Oncol. In press. https://doi.org/10.1016/j.euo.2021.03.006.
Yang B; Yang G; Yao X
Eur Urol Oncol; 2021 Oct; 4(5):852-853. PubMed ID: 34535419
[No Abstract] [Full Text] [Related]
14. Re: Pawel Rajwa, Daniele Robesti, Michael Chaloupka, et al. Outcomes of Cytoreductive Radical Prostatectomy for Oligometastatic Prostate Cancer on Prostate-specific Membrane Antigen Positron Emission Tomography: Results of a Multicenter European Study. Eur Urol Oncol. In press. https://doi.org/10.1016/j.euo.2023.09.006.
Onal C; Elmali A; Cem Guler O
Eur Urol Oncol; 2024 Jun; 7(3):644-645. PubMed ID: 38365504
[No Abstract] [Full Text] [Related]
15. Re: Ost P, Siva S, Brabrand S, et al. PEACE V-Salvage Treatment of OligoRecurrent nodal prostate cancer Metastases (STORM): Acute Toxicity of a Randomized Phase 2 Trial. Eur Urol Oncol. In press. https://doi.org/10.1016/j.euo.2023.09.007.
Montorsi F; Gandaglia G; Barletta F; Briganti A
Eur Urol Oncol; 2024 Feb; ():. PubMed ID: 38418265
[No Abstract] [Full Text] [Related]
16. Reply to Marco Bandini, Andrea Salonia, and Francesco Montorsi's Letter to the Editor re: Laura Elst, Manon T.A. Vreeburg, Hielke Martijn de Vries, et al. Corporal Skip Metastases in Penile Squamous Cell Carcinoma: An Unknown and Distinct Pattern of Spread with Poor Prognosis. Eur Urol Oncol. In press. https://doi.org/10.1016/j.euo.2023.09.005.
Elst L; Vreeburg MTA; Brouwer OR; Albersen M
Eur Urol Oncol; 2024 Mar; ():. PubMed ID: 38493073
[No Abstract] [Full Text] [Related]
17. Re: Guillaume Ploussard, Eric Barret, Gaëlle Fiard, et al. Transperineal Versus Transrectal Magnetic Resonance Imaging-targeted Biopsies for Prostate Cancer Diagnosis: Final Results of the Randomized PERFECT trial (CCAFU-PR1). Eur Urol Oncol. In press. https://doi.org/10.1016/j.euo.2024.01.019.
Lin FX; Yu Y; Xu ZP
Eur Urol Oncol; 2024 May; ():. PubMed ID: 38772750
[No Abstract] [Full Text] [Related]
18. Re: Felix Seelemeyer, David Pfister, Robert Pappesch, et al. Evaluation of a miRNA-371a-3p Assay for Predicting Final Histopathology in Patients Undergoing Primary Nerve-sparing Retroperitoneal Lymphadenectomy for Stage IIA/B Seminoma or Nonseminoma. Eur Urol Oncol. In press. https://doi.org/10.1016/j.euo.2023.10.021.
Urabe F; Yoshioka T; Kimura T
Eur Urol Oncol; 2024 Apr; 7(2):307. PubMed ID: 38238224
[No Abstract] [Full Text] [Related]
19. Reply from authors re: Marko Babjuk. Second resection for non-muscle-invasive bladder carcinoma: current role and future perspectives. Eur Urol 2010;58:191-2 and Giacomo Novara, Vincenzo Ficarra. Does routine second transurethral resection affect the long-term outcome of patients with T1 bladder cancer? Why a flawed randomized controlled trial cannot address the issue. Eur Urol 2010;58:193-4.
Divrik RT; Sahin AF; Ergör G
Eur Urol; 2010 Aug; 58(2):195-6. PubMed ID: 20471156
[No Abstract] [Full Text] [Related]
20. Re: Wei Shen Tan, Aaron Prendergast, Charlotte Ackerman, et al. Adjuvant Intravesical Chemohyperthermia Versus Passive Chemotherapy in Patients with Intermediate-risk Non-muscle-invasive Bladder Cancer (HIVEC-II): A Phase 2, Open-label, Randomised Controlled Trial. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2022.08.003.
Sahoo S; Pandey A; Mandal S; Kumar Das M; Nayak P
Eur Urol; 2023 Feb; 83(2):e47. PubMed ID: 36404203
[No Abstract] [Full Text] [Related]
[Next] [New Search]
